Weekly Analysts’ Ratings Changes for Cambrex (CBM)

A number of firms have modified their ratings and price targets on shares of Cambrex (NYSE: CBM) recently:

  • 10/29/2019 – Cambrex was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Cambrex Corporation is an innovative life sciences company with a refreshingly human approach. Driven by passion, their pharmaceutical products, expertise and technologies accelerate customers’ small molecule therapeutics into markets across the world. The company offers Active Pharmaceutical Ingredients (APIs), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis and controlled substances. Cambrex has transformed from a fine chemical manufacturer to a business with a singular focus on small molecule therapeutics. “
  • 10/28/2019 – Cambrex was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $67.00 price target on the stock. According to Zacks, “Cambrex Corporation is an innovative life sciences company with a refreshingly human approach. Driven by passion, their pharmaceutical products, expertise and technologies accelerate customers’ small molecule therapeutics into markets across the world. The company offers Active Pharmaceutical Ingredients (APIs), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis and controlled substances. Cambrex has transformed from a fine chemical manufacturer to a business with a singular focus on small molecule therapeutics. “
  • 10/22/2019 – Cambrex was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Cambrex Corporation is an innovative life sciences company with a refreshingly human approach. Driven by passion, their pharmaceutical products, expertise and technologies accelerate customers’ small molecule therapeutics into markets across the world. The company offers Active Pharmaceutical Ingredients (APIs), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis and controlled substances. Cambrex has transformed from a fine chemical manufacturer to a business with a singular focus on small molecule therapeutics. “
  • 10/21/2019 – Cambrex was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $67.00 price target on the stock. According to Zacks, “Cambrex Corporation is an innovative life sciences company with a refreshingly human approach. Driven by passion, their pharmaceutical products, expertise and technologies accelerate customers’ small molecule therapeutics into markets across the world. The company offers Active Pharmaceutical Ingredients (APIs), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis and controlled substances. Cambrex has transformed from a fine chemical manufacturer to a business with a singular focus on small molecule therapeutics. “
  • 10/9/2019 – Cambrex was downgraded by analysts at ValuEngine from a “strong-buy” rating to a “buy” rating.

NYSE CBM traded up $0.03 on Friday, reaching $59.82. The stock had a trading volume of 155,870 shares, compared to its average volume of 433,362. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.70 and a current ratio of 2.37. Cambrex Co. has a 12-month low of $33.80 and a 12-month high of $60.29. The business’s 50-day moving average price is $59.65 and its 200 day moving average price is $50.95. The stock has a market cap of $2.02 billion, a P/E ratio of 21.60, a price-to-earnings-growth ratio of 4.67 and a beta of 2.17.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Gabelli Funds LLC purchased a new stake in shares of Cambrex during the third quarter worth approximately $14,458,000. GABELLI & Co INVESTMENT ADVISERS INC. acquired a new position in Cambrex during the third quarter worth $9,259,000. Waddell & Reed Financial Inc. acquired a new position in Cambrex during the second quarter worth $6,945,000. Nuveen Asset Management LLC grew its holdings in Cambrex by 349.9% during the second quarter. Nuveen Asset Management LLC now owns 180,545 shares of the biotechnology company’s stock worth $8,451,000 after acquiring an additional 140,418 shares during the period. Finally, BlackRock Inc. grew its holdings in Cambrex by 2.7% during the second quarter. BlackRock Inc. now owns 5,001,164 shares of the biotechnology company’s stock worth $234,103,000 after acquiring an additional 132,617 shares during the period.

Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as finished dosage forms.

Recommended Story: What are earnings reports?

Receive News & Ratings for Cambrex Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex Co and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply